• 1
    Stenflo J, Ferlund P, Egan W, Roepstorff P 1974 Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71:27302733.
  • 2
    Nelsestuen GL, Zytkovicz TH, Howard JB 1974 The mode of action of vitamin K. Identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249:63476350.
  • 3
    Hauschka PV, Lian JB, Gallop PM 1975 Direct identification of the calcium-binding amino acid γ-carboxyglutamate in mineralized tissue. Proc Natl Acad Sci USA 72:39253929.
  • 4
    Price PA, Urist MR, Otawara Y 1983 Matrix Gla Protein, a new γ-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 117:765771.
  • 5
    Binkley NC, Suttie JW 1995 Vitamin K nutrition and osteoporosis. J Nutr 125:18121821.
  • 6
    Vermeer C, Jie K-SG, Knapen MHJ 1995 Role of vitamin K in bone metabolism. Ann Rev Nutr 15:122.
  • 7
    Shearer MJ 1997 The roles of vitamins D and K in bone health and osteoporosis prevention. Proc Nutr Soc 56:915937.
  • 8
    Shearer MJ 2000 Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 3:433438.
  • 9
    Herz J, Gotthardt M, Willnow TE 2000 Cellular signalling by lipoprotein receptors. Curr Opin Lipidol 11:161166.
  • 10
    Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ 1998 Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr 67:12261231.
  • 11
    Kohlmeier M, Salomon A, Saupe J, Shearer MJ 1996 Transport of vitamin K to bone in humans. J Nutr 126:1192S1196S.
  • 12
    Cooper A 1997 Hepatic uptake of chylomicron remnants. J Lipid Res 38:21732192.
  • 13
    Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C 1990 Heparin effect on bone density. Thromb Haemost 64:286289.
  • 14
    Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Baron AE, Barton PL 1994 A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862869.
  • 15
    Beresford JN, Gallagher JA, Poser JW, Russell RG 1984 Production of osteocalcin by human bone cells in vitro: Effects of 1,25 (OH)2D3, 24,25(OH)2D3, parathyroid hormone and glucocorticoids. Metab Bone Dis Relat Res 5:229234.
  • 16
    Gundle R, Beresford JN 1995 The isolation and culture of cells from explants of human trabecular bone. Calcif Tissue Int 56(Suppl 1):S8S10.
  • 17
    Olivecrona T, Bengtsson-Olivecrona G, Ostergaard P, Liu G, Chevreuil O, Hultin M 1993 New aspects on heparin and lipoprotein metabolism. Haemostasis 23(Supp 1):150160.
  • 18
    Hirsh J, Salzman EW, Marder VJ 1994 Treatment of venous thromboembolism. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW (eds.) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. JB Lippincott, Philadelphia, PA, USA, pp. 13461366.
  • 19
    Mahley RW, Hussain MM 1991 Chylomicron and chylomicron remnant catabolism. Curr Opin Lipidol 2:170176.
  • 20
    Ji Z-S, Fazio S, Lee Y-L, Mahley RW 1994 Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem 269:27642772.
  • 21
    Hussain MM, Mahley RW, Boyles JK, Lindquist PA, Brecht WJ, Innerarity TL 1989 Chylomicron metabolism: Chylomicron uptake by bone marrow in different animal species. J Biol Chem 264:1793117938.
  • 22
    Lucas M, Iverius P-H, Strickland DK, Mazzone T 1997 Lipoprotein lipase reduces secretion of apolipoprotein E from macrophages. J Biol Chem 272:1300013005.
  • 23
    Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA 1997 Changes in serum osteocalcin, plasma phylloquinone, and urinary γ-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 65:779784.
  • 24
    Lian JB, Stein GS, Stein JL, van Wijnen AJ 1999 Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Vitam Horm 55:443509.
  • 25
    Mahley RW, Rall SC 1995 Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: ScriverCR, BeaudetAL, SlyWS, ValleD (eds.) The Metabolic and Molecular Bases of Inherited Disease, 7th ed., vol II. McGraw-Hill, New York, NY, USA, pp. 19531980.
  • 26
    Cullen P, Cignarella A, Brennhausen B, Mohr S, Assmann G, von Eckardstein A 1998 Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 101:16701677.
  • 27
    Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW 1981 Familial dysbetalipoproteinemia: Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits and cows. J Clin Invest 68:10751085.
  • 28
    Weisgraber KH, Innerarity TL, Mahley RW 1982 Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:25182521.
  • 29
    Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr 1981 Type III hyperlipoproteinemia: Defective metabolism of an abnormal apolipoprotein E. Science 211:584586.
  • 30
    Weintraub MS, Eisenberg S, Breslow JL 1987 Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 80:15711577.
  • 31
    Cortner JA, Coates PM, Le N-A, Cryer DR, Ragni MC, Faulkner A, Langer T 1987 Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J Lipid Res 28:195206.
  • 32
    Boerwinkle E, Brown S, Sharrett AR, Heiss G, Patsch W 1994 Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am J Hum Genet 54:341360.
  • 33
    Saupe J, Shearer MJ, Kohlmeier M 1993 Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 58:204208.
  • 34
    Szulc P, Chapuy M-C, Meunier PJ, Delmas PD 1993 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:17691774.
  • 35
    Szulc P, Arlot M, Chapuy M-C, Duboeuf F, Meunier PJ, Delmas PD 1994 Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 9:15911595.
  • 36
    Luukinen H, Kakonen SM, Pettersson K, Koski K, Laippala P, Lovgren T, Kivela SL, Vaananen HK 2000 Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:24732478.
  • 37
    Kohlmeier M, Saupe J, Shearer MJ, Schaefer K, Asmus G 1997 Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int 51:12181221.
  • 38
    Shiraki M, Shiraki Y, Aoki C, Hosoi T, Inoue S, Kaneki M, Ouchi Y 1997 Association of bone mineral density with apolipoprotein E phenotype. J Bone Miner Res 12:14381445.
  • 39
    Kohlmeier M, Saupe J, Schaefer K, Asmus G 1998 Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 62:278281.
  • 40
    Cauley JA, Zmuda JM, Yaffe K, Kuller LH, Ferrell RE, Wisniewski SR, Cummings SR 1999 Apolipoprotein E polymorphism: A new genetic marker of hip fracture risk-The study of osteoporotic fractures. J Bone Miner Res 14:11751181.
  • 41
    Goldhaber P 1965 Heparin enhancement of factors stimulating bone resorption in tissue culture. Science 147:407408.
  • 42
    Fuller K, Chambers TJ, Gallagher AC 1991 Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 147:208214.
  • 43
    Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG 1996 Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:13141320.
  • 44
    Simmons HA, Raisz LG 1991 Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. J Bone Miner Res 12:13011305.
  • 45
    Zambon A, Schmidt I, Beisiegel U, Brunzell JD 1996 Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. J Lipid Res 37:23942404.
  • 46
    Oka K, Wang-Iverson P, Paterniti JR Jr, Brown WV 1989 Interaction of lipoprotein lipase with heparin. Ann NY Acad Sci 556:173180.
  • 47
    Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL 1992 Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins: Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 267:1328413292.
  • 48
    Monreal M, Lafoz E, Olive A, del Rio L, Vedia C 1994 Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71:711.
  • 49
    Shaughnessy SG, Young E, Deschamps P, Hirsh J 1995 The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:13681373.